New York State Medicaid
NYRx Preferred Drug Program - 2024 Therapeutic Class Reviews
Preferred Drug Program Legislation

The New York State Medicaid Drug Utilization Review (DUR) Board intends to review the following therapeutic classes in 2024 as they pertain to the NYRx, the Fee-for-Service Preferred Drug Program (PDP). For the therapeutic classes listed below, new relevant clinical and/or financial information is known to exist.

Therapeutic Category	Therapeutic Class	Previous Review Date
Central Nervous System	Movement Disorder Agents	5/12/2022
	Multiple Sclerosis Agents	7/15/2021
Dermatologic Agents	Anti-Fungals - Topical	5/12/2022
	Immunomodulators - Topical	6/10/2009
Endocrine/Metabolic Agents	Anabolic Steroids - Topical	9/17/2015
	Growth Hormones	9/21/2023
Gastrointestinal	Proton Pump Inhibitors (PPIs)	5/18/2023
Hematological Agents	Hemophilia Agents - Factor VIII	Initial Review
Immunologic Agents	Immunomodulators - Systemic	5/18/2023
Ophthalmics	Anti-inflammatory/Immunomodulators - Ophthalmic	5/13/2021
Ophthalmics	Non-steroidal Anti-inflammatory Drugs - Ophthalmic	4/27/2017
Renal and Genitourinary	Phosphate Binders/Regulators	7/15/2021

Please refer to NYRx Preferred Drug List (PDL) for the list of drugs in the therapeutic class.

As of April 2024, no relevant new clinical and/or financial information is known to exist for the remaining PDP therapeutic classes, since previously reviewed, and the DOH proposes no changes to the NYRx PDL. If interested parties have new relevant clinical information, it can be submitted to dur@health.ny.gov as it becomes available. When submitting new relevant clinical information, please reference the DUR Board and PDP therapeutic Class. DOH will consider new relevant clinical information submitted when developing future DUR Board meeting agendas.

In determining and submitting new clinical information, the previous review dates for all therapeutic classes are available on prior meeting agendas which may be viewed at the DUR Program webpage. New clinical information may include a new drug or drug product

information, new indications, new safety information or new published clinical trials. Comparative evidence is preferred, or placebo controlled when no head-to-head trials are available. Information in abstract form alone, posters, or unpublished data are poor quality evidence for the purpose of review and submission is discouraged.

DUR Board meeting agendas are posted to the DUR Program webpage thirty days prior to the meeting date. Please monitor the DUR Program webpage for DUR Board meeting schedules and agendas.